Coming soon. Join the waitlist

Weight loss, now in a daily pill

The same sustainable weight loss programme you trust; with clinically proven medication, UK clinicians, and longevity experts. Soon available as a simple oral treatment, no injections required.

No commitment. We'll only email you about the oral treatment launch.
Clinically proven Prescribed by UK Clinicians
Woman taking her daily oral weight loss tablet with a glass of water
Dr Luke Pratsides, Chief Medical Officer at Get A Drip
Dr Luke Pratsides
Chief Medical Officer, Get A Drip. GMC registered
"Oral weight loss medication works. What makes our programme different is the clinical rigour behind it: personalised dosing, ongoing review, and real medical support throughout."

Explore oral weight loss medication

Stay up to date
We'll let you know what to expect
Be the first to know
About updates to our clinical treatments
Hand holding a single white oral treatment tablet
No needles
A daily pill instead of weekly injections. Nothing to refrigerate, nothing to inject.
Fits your routine
Take it like any other daily medication, at home or away.
Same clinical care
Prescribed and monitored by the same UK clinicians behind our existing programme.
Whole-person support
Exercise and habit formation support included. Medication is one part of the plan.
Injectable Pen
Weekly injection
~19-21% weight loss (72 weeks)2
Needles involved
Needs cold-chain storage
NEW Oral Treatment
Daily pill
~17% weight loss (64 weeks)1
No needles involved
No cold-chain storage

Oral weight loss treatment is
coming to the UK very soon.

Injection-free, powerful results.

~17%

average body weight loss in clinical trials1

Be the first to access it
Woman holding a tablet and a glass of water in her bedroom

Be first in line

Waitlist members get priority access at launch.

Join the Waitlist

1. OASIS 4: Wharton et al., New England Journal of Medicine (2025)

2. STEP UP: Wharton S, et al. Once-weekly semaglutide 7.2 mg in adults with obesity: a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology. (2025); SURMOUNT-1: Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. (2022)